All Genzyme News
Genzyme
| December 9, 2009 | Genzyme Laboratory Recognized for Quality | | December 8, 2009 | Robert J. Bertolini Elected to Genzyme’s Board of Directors | | December 8, 2009 | Genzyme’s Mozobil Shows Promise in Chemosensitization | | December 7, 2009 | Genzyme Phase 3 Trial of Campath/Fludara Combination Shows Potential Benefit in Second-Line CLL | | December 3, 2009 | Genzyme to Reopen Enrollment in Alglucosidase Alfa Temporary Access Program | | December 1, 2009 | Genzyme Begins Shipping Newly Produced Cerezyme from Allston Plant | | November 18, 2009 | Genzyme Announces Results of Phase 2/3 Trial of Advanced Phosphate Binder | | November 17, 2009 | Data from Mipomersen Phase 3 Trial in hoFH Patients Presented at AHA | | November 16, 2009 | Genzyme Receives Complete Response Letter on Lumizyme Application | | November 13, 2009 | Genzyme Issues Letters to U.S. Healthcare Providers | | October 21, 2009 | Genzyme Reports Third-Quarter Financial Results | | October 20, 2009 | First Patient Enrolled in Phase 3 Trials of Genzyme Oral Capsule for Gaucher Disease | | October 14, 2009 | Scientists Name Genzyme a Top Employer | | October 6, 2009 | Genzyme Receives FDA Complete Response Letter for Clolar | | October 2, 2009 | Genzyme Named to Dow Jones Sustainability World and North American Indexes | | September 24, 2009 | Genzyme’s Campath Meets Primary Endpoint in Phase 3 Combination Therapy Trial for Chronic Lymphocytic Leukemia | | September 23, 2009 | Genzyme Provides Update on Cerezyme and Fabrazyme Supply | | September 11, 2009 | Genzyme’s Alemtuzumab for Multiple Sclerosis Shows Durable Treatment Benefit in Review of Four-Year Phase 2 Trial Data | | September 01, 2009 | FDA Advisory Committee Recommends Randomized Trial to Support Proposed Indication for Clolar in Adult AML | | August 28, 2009 | FDA Advisory Committee to Discuss Genzyme’s Clolar for Adult AML on Sept. 1 | | August 10, 2009 | Genzyme Provides Update on Cerezyme Supply and 2009 Financial Information | | August 5, 2009 | European Commission Approves Genzyme’s Mozobil | | July 31, 2009 | Genzyme Provides Update on Allston Landing Plant | | July 22, 2009 | Genzyme Delivers Solid Second-Quarter Financial Results | | June 25, 2009 | Genzyme Reports Progress Related to Allston Plant | | June 16, 2009 | Genzyme Temporarily Interrupts Production at Allston Plant | | June 12, 2009 | Genzyme Receives European Approval of Renvela for Patients with Chronic Kidney Disease | | June 2, 2009 | Genzyme Completes Transaction with Bayer HealthCare | | May 29, 2009 | Genzyme Receives Positive Opinion for European Approval of Mozobil | | May 21, 2009 | Genzyme Submits All Information Requested by FDA for Lumizyme | | May 20, 2009 | Genzyme and Isis Announce that Mipomersen Phase 3 Study in Patients with Homozygous Familial Hypercholesterolemia Met Primary Endpoint | | May 6, 2009 | Genzyme Provides Outlook for Long-Term Growth at its Analyst Day Meeting | | April 22, 2009 | Genzyme Reports Solid Financial Results for the First Quarter of 2009 | | March 31, 2009 | Genzyme and Bayer HealthCare Enter New Strategic Agreement | | March 19, 2009 | Genzyme Receives Positive Opinion for European Approval of Renvela for Patients with Kidney Disease | | March 2, 2009 | Genzyme Receives Complete Response Letter from FDA on Lumizyme Application | | February 26, 2009 | European Authorities Approve Larger-Scale Production of Genzyme’s Myozyme | | February 19, 2009 | Genzyme Receives Positive Opinion on Myozyme from CHMP | | October 15, 2008 | Genzyme Begins Enrollment in Post-Marketing Study to Evaluate Use of Low Dose Fabrazyme Treatment for Fabry Disease | | September 23, 2008 | Mozobil Receives Priority Review with FDA Action Expected by Year End; Synvisc-ONE FDA Action also Expected by Year End |
|
|
|
|
CONTACT INFORMATION: |
|
Genzyme Therapeutics Ltd,
Genzyme Biosurgery
4620 Kingsgate
Cascade Way
Oxford Business Park South
Oxford
OX4 2SU
Tel: 01865 405200
Fax: 01865 774172
Genzyme Therapeutics Ltd
Genzyme Europe Research
310 Cambridge Science Park
Milton Road
Cambridge
CB4 0WG
Tel: 01223 394000
Fax: 01223 394190
Genzyme Ltd
Genzyme Diagnostics
50 Gibson Drive
Kings Hill
West Malling
Kent
ME19 4AF
Tel: 01732 220022
Fax: 01732 220024
Genzyme Ltd
Haverhill Operations
12 Rookwood Way
Haverhill
Suffolk
CB9 8PU
Tel: 01440 703522
Fax: 01440 716269
Registered Office for Genzyme Therapeutics Ltd
4620 Kingsgate
Cascade Way
Oxford Business Park South
Oxford
OX4 2SU
Company Registration No. 4316333
Registered in England
Registered Office for Genzyme Ltd
37 Hollands Road
Haverhill
Suffolk
CB9 8PU
Company Registration No. 01556886 Registered in England |
|
|
|
Genzyme UK Home
